stockportfolio.pro
Annexon, Inc. (ANNX)
Healthcare · Biotechnology · NasdaqGS
Annexon, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-37.18M | $-63.41M | $-130.32M | $-141.95M | $-134.24M | $-138.20M | $-206.69M |
| Net margin | — | — | — | — | — | — | — |
Source: Annexon, Inc. SEC filings (10-K).
Explore 7 years of Annexon, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ANNX in your portfolio →
Annexon, Inc. financial history by metric
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon, Inc. — frequently asked questions
What is Annexon, Inc.'s revenue?
Annexon, Inc. (ANNX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Annexon, Inc. profitable?
No — ANNX reported a net loss of $-206.69M in fiscal 2025.
What is ANNX's P/E ratio?
Annexon, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Annexon, Inc. have?
As of fiscal year 2025, ANNX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Annexon, Inc.'s market cap?
Annexon, Inc. (ANNX) has a market capitalization of about $785.63M, based on the latest data in our nightly-refreshed cache.
When does Annexon, Inc.'s fiscal year end?
ANNX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Annexon, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.